Lucid Diagnostics Other Current Assets Over Time
| LUCD Stock | USD 1.34 0.14 9.46% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Lucid Diagnostics Performance and Lucid Diagnostics Correlation. Lucid |
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lucid Diagnostics. If investors know Lucid will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lucid Diagnostics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.12) | Revenue Per Share | Quarterly Revenue Growth 0.497 | Return On Assets | Return On Equity |
The market value of Lucid Diagnostics is measured differently than its book value, which is the value of Lucid that is recorded on the company's balance sheet. Investors also form their own opinion of Lucid Diagnostics' value that differs from its market value or its book value, called intrinsic value, which is Lucid Diagnostics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lucid Diagnostics' market value can be influenced by many factors that don't directly affect Lucid Diagnostics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lucid Diagnostics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lucid Diagnostics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lucid Diagnostics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Other Current Assets Analysis
Compare Lucid Diagnostics and related stocks such as Inari Medical, Beyond Air, and PAVmed Series Z Other Current Assets Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NARI | 807.9 K | 807.9 K | 807.9 K | 807.9 K | 807.9 K | 807.9 K | 807.9 K | 807.9 K | 807.9 K | 514.1 K | 2.9 M | 11 M | 10.6 M | 7.1 M | 8.2 M | 6 M |
| XAIR | 53 K | 53 K | 53 K | 53 K | 58 K | 26.0 | 26.0 | 59.2 K | 118.5 K | 131.7 K | 2.6 M | 508 K | 338 K | 6.8 M | 7.8 M | 8.2 M |
| PAVMZ | 3 K | 3 K | 3 K | 3 K | 3 K | 8.8 K | 155.5 K | 88.5 K | 238 K | 328.3 B | 1.7 M | 5.2 M | 3.9 M | 3.8 M | 4.3 M | 4.1 M |
| CLPT | 19.8 K | 19.8 K | 63.2 K | 174.9 K | 29.2 K | 97.2 K | 135 K | 192.7 K | 213.7 K | 357.2 K | 488 K | 1 M | 1.7 M | 1.2 M | 1.7 M | 1.8 M |
| LIVN | 12.8 M | 3.8 M | 4.1 M | 6.6 M | 15 M | 26.6 M | 60.5 M | 39.1 M | 29.6 M | 28.5 M | 155.6 M | 180 M | 358.1 M | 358.7 M | 32.4 M | 46.6 M |
| ELMD | 324.7 K | 1 M | 428.8 K | 397.9 K | 397.8 K | 412.9 K | 393.3 K | 832.2 K | 353.2 K | 353.3 K | 276 K | 1.9 M | 1.6 M | 329 K | 378.4 K | 735.2 K |
| KIDS | 577 K | 577 K | 577 K | 577 K | 577 K | 222 K | 233 K | 831 K | 1.3 M | 2.7 M | 4 M | 4.6 M | 5.4 M | 5.7 M | 6.6 M | 6.9 M |
| SRDX | 3.8 M | 31.3 M | 1.4 M | 1.1 M | 1.7 M | 1.2 M | 1.8 M | 3.6 M | 4.4 M | 5.8 M | 1.7 M | 2.6 M | 7.9 M | 2.9 M | 3.3 M | 3.1 M |
| NPCE | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 1.2 M | 4.5 M | 3.1 M | 2.7 M | 2.4 M | 2.8 M |
| FNA | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 617 K | 3.1 M | 4.7 M | 4 M | 4.6 M | 3.3 M |
| CVRX | 375 K | 375 K | 375 K | 375 K | 375 K | 375 K | 375 K | 375 K | 375 K | 375 K | 605 K | 5.2 M | 4.2 M | 3 M | 2.5 M | 2.9 M |
| LUNG | 30.5 K | 30.5 K | 30.5 K | 30.5 K | 30.5 K | 30.5 K | 8.8 K | 335.2 K | 125 K | 766 K | 3.1 M | 4.8 M | 4 M | 3.6 M | 4.7 M | 5 M |
| IRMD | 77.2 K | 77.2 K | 77.2 K | 117.6 K | 276.5 K | 318 K | 362.9 K | 648.9 K | 526.8 K | 407.8 K | 3.2 M | 4.3 M | 885.1 K | 1.2 M | 1.4 M | 1.1 M |
| OFIX | 2.7 M | 92.1 M | 32.1 M | 26.8 M | 26.6 M | 31.2 M | 19.2 M | 25.9 M | 17.9 M | 20.9 M | 17 M | 20.1 M | 22.3 M | 37.1 M | 25.9 M | 21.3 M |
| ITGR | 2.5 M | 15.3 M | 20.3 M | 12.7 M | 17.9 M | 20.9 M | 22 M | 17.8 M | 15.1 M | 17.9 M | 15.9 M | 27.6 M | 27 M | 28.1 M | 28.4 M | 16.4 M |
Lucid Diagnostics and related stocks such as Inari Medical, Beyond Air, and PAVmed Series Z Other Current Assets description
Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.My Equities
My Current Equities and Potential Positions
| Lucid Diagnostics | LUCD |
Specialization | Health Care, Health Care Equipment & Services |
| Location | New York; U.S.A |
| Exchange | NASDAQ Exchange |
USD 1.34
Check out Lucid Diagnostics Performance and Lucid Diagnostics Correlation. For information on how to trade Lucid Stock refer to our How to Trade Lucid Stock guide.You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Lucid Diagnostics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.